ARAnjna Rani

Anjna Rani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anjna Rani has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Emerging Nanoparticle Therapeutic Approaches for Alzheimer’s Disease: Target Sites and Mechanistic Insights

    by Vikas Singh, Rakhi Mishra, Rupa Mazumder, Avijit Mazumder, Anjna Rani

    Introduction: Alzheimer's Disease (AD) is a progressive neurodegenerative condition and the most frequent cause of dementia among the elderly. AD is characterized by extracellular accumulation of amyloid plaques, neurofibrillary tangles, and glial responses, which result in neuronal and synaptic loss. The ongoing research into therapeutic interventions has shifted from symptomatic management toward disease-modifying strategies, including approaches targeting amyloid aggregation, tau pathology, neuroinflammation, and synaptic repair. Methods: The manuscript presents a thorough analysis of the targeted strategy, with particular emphasis on the application of nanoparticle-based systems for improve the management of Alzheimer’s disease. Studies examining the role of tau protein, Amyloid Beta (Aβ), and other peptides in forming the pathological framework of Alzheimer's disease were included in the analysis. Results: Recent findings indicate that nanoparticle-based approaches have enhanced therapeutic efficacy through targeted drug delivery, improved penetration across the blood-brain barrier, and attenuation of neuroinflammation, thereby offering promising benefits in the management of Alzheimer’s disease. The growing interest in nanotechnology-based interventions for Alzheimer's disease is reflected in a substantial number of patented innovations, including liposomal formulations, cerium oxide nanoparticles, and natural nanoparticle-pharmaceutical compositions. Discussion: Nanoparticle-based therapeutics demonstrate multifaceted efficacy in addressing Alzheimer’s disease pathology. By directly inhibiting the accumulation and expression of key pathogenic targets—such as amyloid-beta and hyperphosphorylated tau—while simultaneously modulating microglial activity and neuroinflammatory cascades, nanotechnology targets mechanisms that traditional therapies often fail to resolve. Conclusion: Moving beyond conventional symptom-focused care, nano-enabled delivery systems offer a scalable strategy to enhance drug efficacy and cross the blood-brain barrier. Future research should prioritize translating these preclinical nanotherapeutic platforms into standardized clinical applications.

  • Advancements in Nanoparticle-based Treatment Approaches for Ocular Inflammation

    by Megha Rani, Rupa Mazumder, Anjna Rani, Rakhi Mishra

    Nanoparticles are small particles, typically 1-100 nm in size, designed as adaptable drug carriers to improve bioavailability, facilitate targeted delivery, and enable controlled release across biological barriers. Ocular inflammation, encompassing vision-threatening conditions such as uveitis, scleritis, and other inflammatory eye diseases, poses significant therapeutic challenges due to both static and dynamic barriers (including the corneal epithelium, tear film, and the blood-retinal barrier). The article comprehensively examines recent developments in nanoparticle-based drug delivery systems designed for ocular therapy, such as polymeric nanoparticles and dendrimers, inorganic nanoparticles, lipid-based systems, and novel platforms like microneedle patches and drugeluting implants. As demonstrated by in vitro models (such as porcine cornea penetration), in vivo animal studies (like rat uveitis models), patents, and developing clinical trials for non-infectious uveitis. These nanotechnologies overcome present limitations through superior targeting to anterior and posterior segments, prolonged residence time, controlled release, reduced toxicity, and also add some of the benefits like antioxidant, anti-inflammatory, and antimicrobial effects that depend on the nanoparticle type. It helps to overcome the poor bioavailability, NSAID-related side effects, and frequent dosing problems of conventional corticosteroids. However, regulatory barriers, scalability, and safety remain very important challenges for clinical translation. This review highlights how nanoparticle- based systems improve ocular bioavailability, reduce dosing frequency in inflammatory eye diseases, and prolong drug residence time, while also identifying key translational challenges related to regulation, scalability, and safety. Several formulations achieved multi-fold increases for days to weeks.

  • Exploring the Role of Immune Checkpoint Inhibitors in Retinoblastoma Prognosis

    by Qusai Malak, Rupa Mazumder, Anjna Rani, Abhijit Debnath, Ankita Kalra

    Retinoblastoma is an intraocular cancer in children with genetic and immunologic complexities that play a significant role in determining their outcome and response to therapy. Although there have been great advancements made in both the diagnosis and management of this condition, the biological and immunologic diversity of the tumors continues to create obstacles in disease management. It is therefore important to have in-depth knowledge of the genetic and immune landscape of retinoblastoma to develop effective and sustainable management options. In this review, we will take a deep dive into the genetic changes associated with retinoblastoma and the tumor microenvironment, which is characterized by the eye's immune privilege. More emphasis will be put on the immune checkpoint molecules PD-1, PD-L1, CTLA-4, B7-H3, and emerging immune checkpoints, including LAG-3, TIM-3, and TIGIT, which help mediate immune escape mechanisms. Increased levels of these immune checkpoints have been shown to contribute to poor prognosis, aggressiveness of the disease, and chemotherapy resistance. Developments in monoclonal and bispecific antibodies, CAR-T therapy, and checkpoint inhibitors derived from phytoconstituents offer a potential solution for targeted therapy in retinoblastoma. This paper highlights the role of genetic and immunological indicators in improving the outcome of retinoblastoma.

  • A Glance at the Recent Nanoparticle-based Therapeutic Approaches Towards Glioblastoma Multiforme

    by Chittathur Midhun Krishna, Rupa Mazumder, Rakhi Mishra, Anjna Rani

    Introduction: Glioblastoma multiforme, abbreviated as GBM, is a malignant form of brain cancer with no definitive cure or method of prevention and an unknown cellular origin that prevents a comprehensive understanding of its complex pathophysiology. Although still in its early stages, nanotechnology-based therapeutic strategies have emerged as a promising solution for overcoming the challenges of drug delivery to the brain. Objective: This manuscript presents a thorough overview of glioblastoma, its underlying biology, and the drawbacks of current treatment options. It also discusses the new strategies aimed at addressing the challenges and limitations of traditional treatment methods for glioblastoma. Methodology: The literature and data covered in this review were collected from research articles published in the last 5 years, with some selected highly relevant earlier works also. The PubMed, Google Scholar, and ClinicalTrials.gov websites were used for data search using keywords including glioblastoma, nanoparticles, nanomedicine, cancer nanotherapy, drug delivery, and blood–brain barrier (BBB), either individually or in combination, to identify relevant studies. Conclusion: The review integrates recent advancements in nanomedicine-based approaches for glioblastoma, highlights their existing challenges, and outlines the future directions for emerging approaches as a promising and actively investigated strategy for targeted drug delivery and therapeutic efficacy.

  • Advancements in Formulation Approaches for Retinoblastoma: An Overview

    by Qusai Malak, Rupa Mazumder, Anjna Rani, Rakhi Mishra

    Introduction: Retinoblastoma (Rb) is an aggressive intraocular tumour that usually affects children and is primarily driven by mutations in the RB1 gene. The treatment of Rb is extremely difficult because of high rates of tumour growth and various anatomical factors that impede effective drug delivery systems. Methods: A comprehensive review of recent publications and patents involving Rb drug delivery, molecular therapy, and immunotherapy was conducted to gain insight into improvements in drug delivery systems and advances in drug delivery for treating retinoblastoma. Results: Novel drug delivery systems such as liposomes, nanoparticles, hydrogels, and microneedles enhance localized delivery and reduce systemic toxicity. Recent patents highlight thermoresponsive hydrogels, enzyme-sensitive multi-drug systems, and biomimetic nanoparticles enabling sustained and targeted release. Gene and RNA-based therapies show promise but face delivery barriers. Immunotherapies, including checkpoint inhibitors and CAR-T cells, enhance antitumor response, while natural bioactive compounds also contribute via antiproliferative and epigenetic mechanisms. Discussions: Despite advances that have been made, difficulties still exist in reaching effective targeting of ocular barriers. New and innovative patents have been created to help overcome current limitations of effective, sustained, targeted, and minimally invasive delivery. Conclusion: Patients using multi-modal personal therapies and integrating advanced delivery methods, molecular targeting, immunotherapy, and patent-backed innovations will change the way retinoblastoma is treated. Future research on early diagnostic markers and designing multiple therapy modalities will help to enhance survival and maintain vision.

  • Open Access

    Fabrication of Curcumin-loaded Olaminosomes for Intracorneal Permeation Enhancement

    by Megha Rani, Rupa Mazumder, Anjna Rani, Rakhi Mishra

    Background: Curcumin, a polyphenolic compound obtained from Curcuma longa, demonstrates potent anti-inflammatory, antioxidant, and immunomodulatory properties, making it a promising candidate for treating ocular inflammatory conditions. However, it faces significant challenges, including low bioavailability, rapid metabolic degradation, poor aqueous solubility, and inadequate corneal penetration. Aim: To formulate and optimise drug-loaded olaminosomes encapsulating Curcumin for enhanced ocular delivery. Methods: Preformulation studies were conducted, including solubility analysis in various solvents and drug excipient compatibility studies using Fourier-Transform Infrared Spectroscopy (FTIR). Olaminosomes, a novel nanovesicular carrier, were prepared using the ethanol injection method, incorporating octadecyl amine, span 80, and oleic acid as lipid, nonionic surfactant, and edge activator to enhance drug entrapment and corneal penetration. Results: The formulation exhibited a vesicle size of 430 nm, a polydispersity index (PDI) of 0.41, an entrapment efficiency of 29.6%, and ex vivo corneal permeation of 40% Curcumin and 60% olaminosomes over 2 hours. Conclusion: These findings underscore the potential of olaminosomes as a promising nanovesicular platform for sustained and targeted ocular drug delivery. Major Findings: Curcumin-loaded olaminosomes were successfully developed with a vesicle size of 430 nm, PDI of 0.41, and entrapment efficiency of 29.6%. The formulation significantly enhanced ex vivo corneal permeation (60%) compared to free Curcumin (40%).


  • Comparative Market Analysis of Generic and Branded Pharmaceuticals in the Indian Healthcare Sector

    by Mohd. Arif, Rakhi Mishra, Rupa Mazumder, Avijit Mazumder, Shruti Varshney, Anjna Rani

    Background: The pharmaceutical industry plays a pivotal role in enhancing healthcare delivery by ensuring the availability of safe, effective, and high-quality medicines. particularly in developing countries like India, where affordability remains a major concern. The ongoing debate between branded and generic medicines significantly impacts healthcare delivery and cost management. Objective: This research aims to estimate the comparative landscape of branded and generic medicines in India, focusing on market trends, pricing differences, stakeholder perceptions, and policy frameworks. Methods: A systematic analytical approach was adopted using secondary data from government reports, published literature, and industry sources. The study evaluates drug pricing, availability, prescription patterns, and consumer awareness to assess market penetration and acceptance. Results: Findings indicate a substantial price difference between branded and generic medicines, with generics being more affordable. However, branded drugs continue to dominate the market due to prescriber preference, perceived quality concerns, and strong marketing strategies. Limited awareness and trust among consumers also hinder the widespread adoption of generics. Conclusion: Generic medicines offer a cost-effective solution to improve healthcare accessibility in India, yet their utilization remains suboptimal. Strengthening regulatory enforcement, increasing awareness, and promoting rational prescribing practices are essential to enhance the acceptance and use of generic medicines. This study is based exclusively on secondary data analysis of government reports, published literature, market databases, and policy documents. Key findings demonstrated that branded medicines were approximately 10-20 times more expensive than generic alternatives, with price differences exceeding 1000% for several commonly prescribed medicines. Branded generics accounted for nearly 80% of the retail market, while public generic medicine schemes contributed only a small share of total utilization.

  • Open Access

    Therapeutic Potential of Phytochemicals in Retinoblastoma: Comprehensive Review

    by Qusai Malak, Rupa Mazumder, Anjna Rani, Rakhi Mishra

    Background: Retinoblastoma is the most common primary intraocular malignancy in children and is primarily caused by biallelic inactivation of the RB1 tumour suppressor gene, leading to dysregulation of the cell cycle. Despite advances in multimodal treatment approaches such as systemic and intra-arterial chemotherapy, focal therapies, radiotherapy, and enucleation, current treatment strategies remain limited due to significant systemic and ocular toxicities, chemoresistance, and suboptimal eye and vision preservation, particularly in resource-limited settings. Aim: The present review aims to evaluate the therapeutic potential of phytoconstituents in the management of retinoblastoma and to highlight their role as safer, multi-target anticancer agents in paediatric ocular oncology. Methods: Literature search was conducted using various databases like PubMed, Google Scholar and Web of Science with keywords like retinoblastoma, RB1, genetics, signalling pathways and phytochemicals having anticancer properties. Discussion: Phytochemicals play an anticancer role in retinoblastoma through various signalling pathways like NF-κB, CDK, JAK/STAT MAPK/ERK and PI3K/AKT/mTOR. The phytochemicals show various activities like pro-apoptotic, anti-angiogenic and anti-invasive properties. Conclusion: Phytoconstituents represent promising adjuncts or alternatives to conventional retinoblastoma therapies. However, further preclinical and clinical investigations are required to overcome formulation challenges such as ocular barriers and poor solubility, and to translate these natural compounds into effective therapeutic strategies. Major Finding: Phytochemicals show promise in retinoblastoma by targeting multiple oncogenic pathways with low toxicity, making them potential candidates for drug development. Their ability to induce apoptosis, inhibit tumour progression, and enhance therapeutic efficacy further supports their potential as safer, more effective alternatives for retinoblastoma management.

  • Open Access

    Proteolysis targeting chimeras (PROTAC) for targeting Alzheimer’s disease

    by Archna Singh, Anjna Rani, Avijit Mazumder